曲美他嗪联合三磷酸腺苷在冠心病伴心功能不全治疗中的应用效果  

Application effect of trimetazidine combined with adenosine triphosphate in the treatment of coronary heart disease with cardiac insufficiency

作　　者：钟扬 ZHONG Yang(Department of Cardiovascular Medicine,Dalian Fifth People’s Hospital,Dalian 116000,China)

机构地区：[1]大连市第五人民医院心血管内科,116000

出　　处：《中国实用医药》2022年第2期119-122,共4页China Practical Medicine

摘　　要：目的研究曲美他嗪联合三磷酸腺苷在冠心病伴心功能不全治疗中的应用效果。方法110例冠心病伴心功能不全患者,以就诊单双号分为常规组和联合组,各55例。常规组采用曲美他嗪治疗,联合组采用曲美他嗪联合三磷酸腺苷治疗。对比两组患者治疗前后的心功能指标,死亡情况,不良反应发生情况。结果治疗后,两组患者的左室射血分数、每分输出量高于本组治疗前,左室收缩末期内径、左室舒张末期内径小于本组治疗前,且联合组患者的左室射血分数(57.92±1.25)%、每分输出量(5.49±0.62)L/min高于常规组的(42.66±1.41)%、(3.97±0.39)L/min,左室收缩末期内径(45.33±2.19)mm、左室舒张末期内径(48.34±3.30)mm小于常规组的(59.68±2.45)、(63.21±2.98)mm,差异具有统计学意义(P<0.05)。跟踪回访12个月,联合组患者的死亡率3.64%低于常规组的14.55%,差异具有统计学意义(P<0.05)。两组患者的不良反应发生率对比,差异无统计学意义(P>0.05)。结论曲美他嗪联合三磷酸腺苷治疗冠心病伴心功能不全能够使患者的心功能得到有效改善,延长患者的预后生存期限,且联合用药未加重患者的用药不良反应,具有较高的用药安全性,临床应用价值较高。Objective To study the application effect of trimetazidine combined with adenosine triphosphate in the treatment of cardiac insufficiency with coronary heart disease.Methods A total of 110 patients with coronary heart disease and cardiac insufficiency were divided into conventional group and combination group,with 55 cases in each group.The conventional group was treated with trimetazidine,and the combination group was treated with trimetazidine and adenosine triphosphate.The cardiac function indexes before and after treatment,mortality,and occurrence of adverse reactions were compared between the two groups.Results After treatment,the left ventricular ejection fraction and cardiac output of the two groups were higher than those of this group before treatment,and the left ventricular end-systolic diameter and left ventricular end-diastolic diameter were less than those of this group before treatment;the left ventricular ejection fraction(57.92±1.25)%and cardiac output(5.49±0.62)L/min of the combination group were higher than(42.66±1.41)%and(3.97±0.39)L/min of the conventional group,and the left ventricular end-systolic diameter(45.33±2.19)mm and left ventricular end-diastolic diameter(48.34±3.30)mm were less than(59.68±2.45)and(63.21±2.98)mm of the conventional group;all differences were statistically significant(P<0.05).At 12 months of follow-up,the mortality rate 3.64%in the combination group was lower than 14.55%in the conventional group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of trimetazidine and adenosine triphosphate for the treatment of patients with coronary heart disease and cardiac insufficiency can effectively improve the patient's cardiac function and prolong the patient's prognostic survival time,and the combination of the two drugs does not aggravate the adverse drug reactions of the patients.It has high drug safety and high clinic

关 键 词：曲美他嗪 三磷酸腺苷 冠心病伴心功能不全 应用效果 预后情况 

分 类 号：R541.4[医药卫生—心血管疾病]